Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Journal of Cystic Fibrosis

Volumn 14, Issue 1, 2015, Pages 111-119

  Tiddens, H A W M ^a   De Boeck, K ^b   Clancy, J P ^c   Fayon, M ^d   H G M , Arets ^e   Bresnik, M ^f   Derchak, A ^f   Lewis, S A ^g   Oermann, C M ^h  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f GILEAD SCIENCES   (United States)

^g Gilead Sciences   (United States)

^h CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Aerosolized antibiotics; Antipseudomonal; P. aeruginosa; Pediatric; Respiratory infections

Indexed keywords

AZTREONAM; ANTIINFECTIVE AGENT;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CHILD; COUGHING; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERADICATION THERAPY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RHINORRHEA; SCHOOL CHILD; SIDE EFFECT; SPUTUM ANALYSIS; SPUTUM CULTURE; THROAT CULTURE; TREATMENT DURATION; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INFANT; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-BACTERIAL AGENTS; AZTREONAM; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84918771958     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.06.003     Document Type: Article

References (32)

1. Döring G., Høiby N., Consensus Study Group Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
2. Frederiksen B., Lanng S., Koch C., Høiby N. Improved survival in the Danish Center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996, 21:153-158.
3. Frederiksen B., Koch C., Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335.
4. Valerius N.H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
5. Wiesemann H.G., Steinkamp G., Ratjen F., Bauernfeind A., Przyklenk B., Döring G., et al. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998, 25:88-92.
6. Munck A., Bonacorsi S., Mariani-Kurkdjian P., Lebourgeois M., Gérardin M., Brahimi N., et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001, 32:288-292.
7. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704.
8. Ratjen F., Döring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001, 358:983-984.
9. Griese M., Müller I., Reinhardt D. Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Eur J Med Res 2002, 7:79-80.
10. Gibson R.L., Emerson J., McNamara S., Burns J.L., Rosenfeld M., Yunker A., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849.
11. Lee T.W., Brownlee K.G., Denton M., Littlewood J.M., Conway S.P. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004, 37:104-110.
12. Starner T., McCray P.B. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005, 143:816-822.
13. Gibson R.L., Emerson J., Mayer-Hamblett N., Burns J.L., McNamara S., Accurso F.J., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007, 42:610-623.
14. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
15. Schelstraete P., Deschaght P., Van Simaey L., Van Daele S., Haerynck F., Vaneechoutte M., et al. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. J Cyst Fibros 2010, 9:99-103.
16. Taccetti G., Bianchini E., Cariani L., Buzzetti R., Costantini D., Trevisan F., et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012, 67:853-859.
17. Proesmans M., Vermeulen F., Boulanger L., Verhaegen J., De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013, 12:29-34.
18. Schelstraete P., Haerynck F., Van daele S., Deseyne S., De Baets F. Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros 2013, 12:1-8.
19. Borowitz D., Robinson K.A., Rosenfeld M., Davis S.D., Sabadosa K.A., Spear S.L., et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009, 155(6 Suppl.):S73-S93.
20. Döring G., Flume P., Heijerman H., Elborn J.S., Consensus Study Group Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012, 11:461-479.
21. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
22. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
23. Oermann C.M., Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., McCoy K.S., Montgomery A.B., et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010, 45:1121-1134.
24. Assael B.M., Pressler T., Bilton D., Fayon M., Fischer R., Chiron R., et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013, 12:130-140.
25. Quittner A.L., Buu A., Messer M.A., Modi A.C., Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005, 128:2347-2354.
26. Speijer H., Savelkoul P.H., Bonten M.J., Stobberingh E.E., Tjhie J.H. Application of different genotyping methods for Pseudomonas aeruginosa in a setting of endemicity in an intensive care unit. J Clin Microbiol 1999, 37:3654-3661.
27. Wang X., Dockery D.W., Wypju D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
28. Quittner A.L., Modi A.C., Wainwright C., Otto K., Kirihara J., Montgomery A.B. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009, 135:1610-1618.
29. Retsch-Bogart G.Z., Burns J.L., Otto K.L., Liou T.G., McCoy K., Oermann C., et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008, 43:47-58.
30. Summary of product characteristics, Cayston Available at:. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000996/WC500019992.pdf.
31. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165:847-856.
32. European Medicines Agency Report of the workshop on endpoints for cystic fibrosis clinical trials 2012, [Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/12/WC500136159.pdf].